Clinical trial NCT00619359 - References

Chemotherapy-Induced Nausea and Vomiting (CINV) — Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

Citation(s)

•   Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J
  Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: rand

Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability & Efficacy of a Single Dose of Intravenous MK0517 for Prevention of Chemotherapy-Induced Nausea & Vomiting Associated With Cisplatin Chemo

Details for clinical trial NCT00619359